pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,669 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1848Endpoints1433Fierce Biotech751BioSpace741BioPharma Dive543raps245onclive165fda recalls117
therapy area
allOncology12789Rare Disease3303Immunology2977Cardiology2834Hematology2276Pulmonology2221Vaccines
  • BMS abandons $100 million Orum degrader-antibody conjugate after early phase-1 results
    Bristol Myers Squibb has decided to stop development of the degrader‑antibody conjugate it purchased from Orum Therapeutics for $100 million after reviewing data from a phase‑1 trial. The experime…
    Fierce Biotech · 2mo agoDealNegative↗ source
  • Electra Therapeutics raises $350 million in oversubscribed IPO
    Electra Therapeutics, a South San Francisco biotech focused on inflammation, completed its Nasdaq IPO, selling 23.3 million shares at $15 each and generating $350 million in gross proceeds. This a…
    Fierce Biotech · 2mo agoDealPositive↗ source
← prev
page 53 of 147
next →
fda medwatch113
globenewswire health73
fda press59
1823
Psychiatry & CNS1227
Ophthalmology1125
Endocrinology & Metabolism794
Pain787
Nephrology779
  • Biopharma prediction markets raise insider-info concerns, regulators weigh oversight
    Prediction markets are emerging as platforms where participants can wager on biopharma events such as clinical trial results and FDA approvals. The format allows crowds to aggregate expectations ab…
    Fierce Biotech · 2mo agoNeutral↗ source
  • HCA Healthcare sues Independence Blue Cross over $345,000 in unpaid Texas hospital claims
    Several Texas hospitals owned by HCA Healthcare have filed a lawsuit against Independence Blue Cross, a Philadelphia‑based insurer, seeking more than $345,000 in unpaid medical claims dating back r…
    STAT · 2mo agoRegulatoryNegative↗ source
  • FDA faces nominee hearing, hiring woes and reviews of psychedelics and testosterone therapies
    A Senate committee set a hearing for President Trump's pick to lead the FDA, highlighting the political scrutiny of the agency's top leadership. New reporting reveals ongoing hiring challenges at…
    raps · 2mo agoRegulatoryNeutral↗ source
  • Artelo’s oral cannabinoid agonist matches semaglutide weight loss in obese mice, doubles effect when combined
    Artelo Biosciences reported that its oral dual cannabinoid agonist, ART27.13, produced weight loss in diet‑induced obese mice that was comparable to the GLP‑1 receptor agonist semaglutide. In a fo…
    Fierce Biotech · 2mo agoPositive readoutPositive↗ source
  • Doctors urged to tell patients Asian glow signals health risk, not harmless quirk
    Brian Zhang, a second-year medical student at Stanford and student body president, wrote an opinion piece urging doctors to discuss the so-called "Asian glow" with patients. The facial flushing th…
    STAT · 2mo agoNeutral↗ source
  • Panel discusses how questions about health equity shape public trust in science
    Anil Oza reported that he participated in a National Academies of Science roundtable focused on population health and how research communication influences public trust. The discussion highlighted…
    STAT · 2mo agoNeutral↗ source
  • IN8bio appoints Oxana Polyakova as senior vice president of R&D
    IN8bio announced a new senior vice president for research and development. Oxana Polyakova joins the company after serving as chief scientific officer at LAVA Therapeutics. Her background in drug…
    STAT · 2mo agoPositive↗ source
  • Geriatrician urges careful use of AI predictions for older patients
    Artificial intelligence tools are being added to electronic health records to flag patients at risk for conditions such as sepsis, falls or even death. The ease of integration has led many clinicia…
    STAT · 2mo agoNeutral↗ source
  • Rise in Young Men Seeking Cosmetic Surgery Driven by Social Media Influence, Surgeon Observes
    A board‑certified plastic surgeon in Boston reports that more young men are now filling her waiting room than ever before, making men the fastest‑growing group in aesthetic procedures. Procedures…
    STAT · 2mo agoNeutral↗ source
  • GF Blends recalls AIP flour and flatbread mixes over undeclared wheat gluten
    GF Blends announced a recall of its Truly AIP All Purpose Flour and Bread Mix and the EAT G.A.N.G.S.T.E.R. Flat Bread Pizza Mix because testing found undeclared wheat gluten. The products were mad…
    fda recalls · 1mo agoRegulatoryNegative↗ source
  • Clinical trial enrollment crisis threatens billions in revenue and patient access
    Clinical trials are struggling with enrollment, with about 80% missing timelines and less than 5% of eligible adult cancer patients participating. Delays have huge financial impact; each day a pha…
    Fierce Biotech · 2mo agoNegative↗ source
  • North Immunology to go public via reverse merger with Aethlon, targeting eczema market
    North Immunology, an early-stage biotech developing a dual-acting antibody for eczema, announced plans to become a public company through a reverse merger with Aethlon Medical. The transaction wil…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Roche inks $1 billion deal with Dualitas to screen 300,000 bispecific combos for immunology and inflammation
    Roche has agreed to pay Dualitas Therapeutics an upfront $36.5 million as part of a broader agreement that could be worth up to $1 billion. The collaboration will use Dualitas’s DualScreen platfor…
    Fierce Biotech · 2mo agoDealPositive↗ source
  • England's NHS to fund AstraZeneca's Enhertu for metastatic breast cancer after U.K.-U.S. pricing pact
    English health authorities have agreed to provide AstraZeneca's breast cancer drug Enhertu through the NHS, ending a multi-year dispute over its availability. The decision will make the drug acces…
    STAT · 2mo agoDealPositive↗ source
  • Novo and Orbis strike up to $1.4 billion partnership to develop oral peptide macrocycles for cardiometabolic disease
    Novo Pharmaceuticals has entered a partnership with fellow Danish firm Orbis Medicines that could be worth as much as $1.4 billion. The agreement includes upfront payments, downstream payouts and r…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Lisata acquires Marea Therapeutics, securing $225M financing to advance two mid-stage drugs
    Lisata Therapeutics completed a stock-for-stock acquisition of biotech startup Marea Therapeutics. The transaction includes a $225 million financing round led by existing backers such as Forbion,…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • ARPA-H launches SPECTRA program to advance autism diagnosis and precision care
    ARPA-H announced the launch of the Systems for Phenotypic Evaluation, Clinical Trajectories, Response, and Agency (SPECTRA) program, a new effort aimed at transforming autism diagnosis and precisio…
    Fierce Biotech · 2mo agoRegulatoryPositive↗ source
  • FDA staffing shortage limits ability to hire new employees, raising concerns for health-care oversight
    STAT's D.C. Diagnosis newsletter reports that the FDA is experiencing a staffing bottleneck, with too few current employees to bring on additional hires. The shortage could slow the agency's capac…
    STAT · 2mo agoRegulatoryNegative↗ source
  • Study finds purer fentanyl will not curb U.S. overdose deaths
    A new study highlighted that increasing the purity of fentanyl is unlikely to lower the number of overdose fatalities in the United States. Researchers noted that while purer fentanyl may be more…
    STAT · 2mo agoNegative↗ source
  • Sellas’ Phase 3 REGAL AML Immunotherapy Study Delayed, Forecast to Miss Survival Endpoint
    Sellas Life Sciences Group’s experimental immunotherapy galinpepimut‑S (GPS) is being tested in a Phase 3 REGAL trial for patients with acute myeloid leukemia in a second remission. The study has b…
    STAT · 2mo agoNegative↗ source
  • Lisata Therapeutics merges with Marea Therapeutics in reverse merger after failed Kuva deal
    Lisata Therapeutics, a solid tumor biotech, announced a stock-for-stock merger with cardiovascular specialist Marea Therapeutics after a previous merger attempt with Kuva Labs collapsed. The trans…
    Fierce Biotech · 2mo agoDealNeutral↗ source
  • Roche partners with Dualitas Therapeutics in up to $1 billion deal to screen bispecific antibodies for immune diseases
    Roche has committed $36.5 million up front to biotechnology startup Dualitas Therapeutics under a research partnership that could total up to $1 billion in milestone payments and royalties. The agr…
    BioPharma Dive · 2mo agoDealPositive↗ source
  • Rare inherited EGFR mutation raises lung cancer risk 62-fold in never-smokers, 25-fold in smokers
    Researchers examined genotyping data from 23andMe covering 3.37 million individuals and found the T790M germline mutation in about one out of every 15,850 people. The study reported that carriers…
    Fierce Biotech · 2mo agoNeutral↗ source